Treats infections caused by susceptible strains of the designated microorganisms in the…. ANDA 65425, held by Amneal Pharmaceuticals. Demeclocycline Hydrochloride.
As of Nov 21, 2026, ANDA 65425 (Demeclocycline Hydrochloride), held by Amneal Pharmaceuticals, was first approved by FDA on Feb 27, 2008, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 27, 2008 | Original application | Approved | None posted |
| Demeclocycline Hydrochloride150MG · tablet;oral | Demeclocycline Hydrochloride | Rx |
| Demeclocycline Hydrochloride300MG · tablet;oral | Demeclocycline Hydrochloride | Rx |
| Feb 5, 2013 | Supplement 2Labeling | Approved | None posted |
| Feb 27, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters